Judge Rules FDA’s Denial of Exclusivity to Amneal Was Legal

Drug Industry Daily
A federal judge ruled that the FDA’s denial of exclusivity of a generic version of Namenda XR was lawful, writing that the agency’s request for more information from an ANDA applicant does not constitute a new regulatory hurdle.

To View This Article:


Subscribe To Drug Industry Daily